MedTrace Logo

MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer

NCT02578602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2015-10-19

No results posted yet for this study

Summary

This pilot clinical trial studies magnetic resonance imaging (MRI) with gadoxetate disodium in measuring tumors in patients with liver cancer. Diagnostic procedures, such as MRI with gadoxetate disodium, may help find and diagnose liver cancer and find out how far the disease has spread. It is not yet known whether MRI with gadoxetate disodium provides a more precise measurement of liver tumors than standard computed tomography (CT).

Conditions

  • Adult Hepatocellular Carcinoma
  • Advanced Adult Hepatocellular Carcinoma
  • BCLC Stage 0 Adult Hepatocellular Carcinoma
  • BCLC Stage A Adult Hepatocellular Carcinoma
  • BCLC Stage B Adult Hepatocellular Carcinoma
  • BCLC Stage C Adult Hepatocellular Carcinoma
  • BCLC Stage D Adult Hepatocellular Carcinoma
  • Localized Non-Resectable Adult Liver Carcinoma
  • Localized Resectable Adult Liver Carcinoma

Interventions

DRUG

Gadoxetate Disodium

Given IV

DEVICE

Magnetic Resonance Imaging

Undergo MRI with gadoxetate disodium

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Gilbert Whang · University of Southern California

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2014-11-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02578602 on ClinicalTrials.gov